Well this is some good news. Remdesivir appears to be hanging in there with its clinical trials.
The key part of this in my mind is that it is showing effectiveness on severe patients. That’s what we want to see, an antiviral working on people with severe symptoms. That is a good sign.
Gilead’s stock is going through the roof in after hours trading. So people like what they see here.